Background: Type 1 autoimmune pancreatitis (AIP) is the pancreatic manifestation of IgG4-related disease. However, this benign disease can result in the peripancreatic vascular involvement (PVI) on occasion, which increases the difficulty of diagnosis and treatment of this clinical entity as well as for differentiating it from pancreatic malignancies.
Methods: We retrospectively reviewed the information on demographics, clinical presentation, laboratory, imaging and endoscopic findings of 101 hospitalized patients with type 1 AIP treated in our department. All the patients were divided into non-PVI and PVI groups according to the first hospitalized medical data. Univariate and multivariate analyses were performed to analyse the potential predictive parameter(s) of PVI in AIP patients.
Results: Among the 101 type 1 AIP patients, 52 (51.5%) exhibited PVI, with a male/female ratio 5.5:1. Their average age was 58.37±8.68 years old. Univariate analysis revealed that the location of pancreatitis lesions, including the pancreatic tail (P=0.010), the presence of splenomegaly (P=0.001) and the white blood cell (WBC) number in peripheral blood (P=0.020), were significantly associated with PVI. The location of pancreatitis lesions, including the pancreatic tail (P=0.023), and the presence of splenomegaly (P=0.010) were found to be independent predictors of the development of PVI by a multivariable regression analysis. A total of 18 out of 25 patients in PVI group who underwent corticosteroid treatment and no less than 6 months radiological follow-up showed improvement in vascular lesions, and no case exhibited exacerbation of PVI lesions during follow-up. Of 36 patients in non-PVI group who were followed up for no less than 6 months, only one case exhibited PVI.
Conclusions: This retrospective study demonstrated that type 1 AIP was associated with a high proportion of PVI. Pancreatic tail involvement and splenomegaly may predict the PVI in type 1 AIP. PVI lesions are reversible in a subset of patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186208 | PMC |
| http://dx.doi.org/10.21037/hbsn-21-82 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultrasound-guided percutaneous core-needle biopsy for the diagnosis of type 1 autoimmune pancreatitis.
Abdom Radiol (NY)
January 2025
First Affiliated Hospital Zhejiang University, Hangzhou, China.
Purpose: This study aimed to investigate the usefulness of ultrasound-guided core-needle biopsy (US-CNB) for diagnosing type 1 AIP and evaluate the radiological outcomes following steroid therapy.
Materials And Methods: From January 2017 to June 2023, patients with pathology results containing "lymphoplasmacytic infiltration" and "fibrosis" were enrolled. The detection rate of level 1 histology by International Consensus Diagnostic Criteria (ICDC) and the contribution of US-CNB were assessed.
Association of nitric oxide levels and lipid profile with endothelial dysfunction in type 2 diabetic patients.
J Res Med Sci
October 2024
Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraidah, Saudi Arabia.
Article Synopsis
- Evidence-based screening is essential for detecting myocardial ischemia in high-risk diabetics, particularly by analyzing nitric oxide levels, lipid profiles, and atherogenic indices in those with coronary artery disease (CAD).
- A study involved 50 diabetics with CAD, 30 without CAD, and 23 healthy individuals, measuring various biochemical parameters and plasma nitric oxide through the Griess reaction.
- Results indicated that diabetics with CAD had elevated levels of nitric oxide and triglycerides, whereas their cholesterol levels were lower, and there was a significant positive correlation between nitric oxide and glycated hemoglobin, highlighting the link between chronic hyperglycemia and potential vascular complications in diabetes.
The Role of the Atherogenic Index of Plasma and the Castelli Risk Index I and II in Cardiovascular Disease.
Cureus
November 2024
Department of Internal Medicine, M. S. Ramaiah Medical College, Bengaluru, IND.
Introduction: Metabolic syndrome (MS), identified by abdominal obesity, insulin resistance, hypertension, and/or dyslipidemia, occurs across all BMI (body mass index) ranges and increases the risk of atherosclerotic cardiovascular (CV) diseases and type II diabetes. The Atherogenic Index of Plasma (AIP) and Castelli Risk Index (CRI) I & II are ratios that can be calculated from a simple lipid profile test. These ratios are independent risk factors for CV diseases and have been shown to be increased in angiographically confirmed coronary artery disease (CAD) patients.
View Article and Find Full Text PDFNational Poison Data System Annual Report: under the hood.
Clin Toxicol (Phila)
December 2024
Indiana Poison Center, Indiana University Health, Lebanon, Indiana, USA.
Introduction: The 41st National Poison Data System Annual Report from America's Poison Centers is published in this issue of This Commentary focuses on comparing the different poisoning-related surveillance systems in the United States while highlighting some of the strengths and weaknesses of the National Poison Data System. It also reviews the process underlying the fatality review section of the Annual Report.
Comparison Of Poisoning Surveillance Systems: In order to place the data reported by the National Poison Data System in context, the National Poison Data System was compared to other available poisoning surveillance systems in the United States: the American College of Medical Toxicology's Toxicology Investigators Consortium (ToxIC) Registry, the Centers for Disease Control and Prevention Injury Prevention and Control Web-based Injury Statistics Query and Reporting System (WISQARS) which partners with the Consumer Products Safety Commission's National Electronic Injury Surveillance System - All Injury Program (NEISS-AIP), and the Centers for Disease Control and Prevention Wide-ranging ONline Data for Epidemiologic Research (CDC WONDER) database.
Clinical relevance of midkine as a biomarker predicting atherosclerotic risk factors in individuals with type-2 diabetes mellitus: a cross-sectional study.
J Diabetes Metab Disord
June 2025
Iraqi Ministry of Health, Baghdad, Iraq.
Objective: Midkine (MK) is a member of a small protein family that includes pleiotrophin. MK levels are elevated in obese patients and have a pro-arthrogenic effect through various pathophysiological processes including vascular inflammation and atherogenesis. This study aimed to investigate the association between serum MK levels and several atherosclerotic risk factors in patients with type 2 diabetes mellitus (T2DM).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!